Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CS20 Bivalent PRRSV Vaccine
- Development stage
- Preclinical
- Lead developer
- Black Cat Bio
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Intradermal
01
Overview
CS20 Bivalent PRRSV Vaccine is a veterinary biologic in preclinical development by Black Cat Bio for the prevention of Porcine Reproductive and Respiratory Syndrome (PRRS) in swine. The vaccine is engineered using a proprietary 'reprogrammable vaccine technology' and is bivalent, targeting both Type 1 (European) and Type 2 (North American) strains of the PRRS virus. It is currently undergoing controlled live pig challenge studies to generate the necessary efficacy and safety data for regulatory submission. The dual-action approach is intended to provide broad protection against the diverse strains of PRRSV that impact the global swine industry.
- Other names
- CS20CS-20CS 20
02
Targets
PRRSV (Porcine reproductive and respiratory syndrome virus)
Beyond the preview
Go deeper on CS20 Bivalent PRRSV Vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CS20 Bivalent PRRSV Vaccine.